ClinicalTrials.gg
TerminatedNCT03099499Updated Nov 3, 2026Results posted

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

A Phase 2 interventional study of ONC201 in Endometrial Cancer, sponsored by Fox Chase Cancer Center. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Fox Chase Cancer Center · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Slow accrual
Updated Oct 14, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Enrollment
491st of 591
19 · median 60
Started
2017
with 23 others
Phase 2
178 of 715
34 open now
Registered
288th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 491st largest by enrollment of the 591 interventional ones that give a count, is one of 24 that started in 2017, is one of 178 in phase 2, and was the 288th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

190 more — sign in →

All 195 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

ONC201 is a small molecule which selectively targets the G protein-coupled receptor DRD2. Downstream of target engagement, ONC201 activates the integrated stress response (ISR) in tumor cell leading to inactivation of Akt and extracellular signal-regulated kinase (ERK) signaling as well as induction of the TRAIL pathway. ONC201 also inhibits dopamine receptor 2 (DRD2), resulting in anti-tumor responses in preclinical models. Single agent ONC201 has been examined in open-label Phase I studies in patients with advanced, treatment refractory solid malignancies. Due to its differential anti-proliferative and pro-apoptotic response in tumor cells, treatment was overall well tolerated, and the recommended phase II dose of ONC201 was set at 625mg every three weeks. An additional dose-escalation phase I study (NCT02609230) is further evaluating weekly versus three week dosing in patients with advanced solid tumors and multiple myeloma. Preliminary data from these phase I studies suggests a possible clinical benefit in patients with advanced, chemo-refractory endometrial cancers, with at least one mixed response noted in a patient with clear cell histology.

Hypothesis: Single agent ONC201 will demonstrate clinical benefit in women with recurrent or metastatic endometrial cancers, especially in those women with alterations in the Phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of Rapamycin (mTOR) pathway.

03

Conditions studied

  • Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have confirmed or recurrent endometrial cancer. Eligible histologies include but are not limited to endometrioid, serous, clear cell, carcinosarcoma, adenosquamous, and mixed histologies.
  2. Patients must have , defined as at least one lesion that can be accurately measured in at least one dimension in accordance with criteria v. 1.1
  3. Must have radiographic disease progression after 1 line of systemic cytotoxic therapy for metastatic disease or with progression within 12 months of completing chemotherapy
  4. Available archived tissue will be provided for correlative studies
  5. Age > 18 years.
  6. (ECOG) performance status of 0, 1, or 2
  7. Patients must have adequate bone marrow, hepatic and renal function as defined below:

    • Leukocytes > 3,000/micro-liter (mcl)
    • > 1,500/mcL
    • > 100,000/mcL
    • Total ≤1.5 (ULN)
    • / Alanine aminotransferase (AST/ALT) \< 2 ULN
    • Creatinine ≤1.5 ULN OR
    • > 60 Ml/min/1.73 m2 for patients with creatinine levels above ULN calculated using Calvert formula
  8. Prior chemotherapy, hormonal and radiation therapy administered in the adjuvant setting will be allowed.
  9. at least 3 months
  10. Ability to understand and willingness to sign a written and HIPAA consent document
  11. Patients must be surgically sterile or be , or must agree to use effective during the period of the trial and for at least 90 days after completion of treatment.

Exclusion criteria

Exclusion Criteria:

  1. No prior treatment with ONC201
  2. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  3. The subjects who have not recovered to baseline or ≤ Grade 1 from related toxicity to all prior therapies will be excluded. Patients with Non-serious adverse events such as alopecia, fatigue, weakness, loss of appetite and nausea that are non-significant will not be excluded.
  4. Any other prior from which the patient has been disease free for less than 3 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site.
  5. The subject is unable to swallow capsules
  6. Patients receiving any other agents
  7. Patients with symptomatic are excluded. Patients with asymptomatic and treated central nervous system (CNS) may participate in this trial. The patient must have completed any prior treatment for CNS metastases > 28 days prior to study entry including radiotherapy or surgery. for the treatment of brain metastasis are not permitted, and patients must be stable off steroid treatment for 4 weeks prior to enrollment
  8. Uncontrolled inter-current illness including, but not limited to ongoing or active infection. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, or symptomatic pulmonary embolism.
  9. Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed.
  10. Known (HIV)-positive patients on combination antiretroviral therapy
  11. Known history of Virus (HBV) or Virus (HCV) infection.
  12. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.
  13. Pregnant or breast feeding. Refer to section 4.4 for further details.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    ONC201 treatment Arm

    Drug: ONC201

Interventions

  • DrugDordaviproneStudies of DordaviproneDordaviprone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Rate at 12 Weeks

    PFS will be calculated from the day of starting the treatment until 12 weeks. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: 12 weeks

  2. Objective Response Rate (ORR) as Determined by Response Criteria In Solid Tumors (RECIST) 1.1 Criteria

    ORR will be calculated from the day of starting the treatment until disease progression. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: 1-2 years

Secondary outcomes

  1. Duration of Response

    Duration of response will be determined from the time when a partial or complete response is seen until disease progression

    Time frame: 1-2 years

  2. Duration of Stable Disease

    Duration of stable disease will be calculated from the time of first treatment until disease progression

    Time frame: 1-2 years

  3. Median Progression Free Survival

    Progression free survival will be calculated from the time of the start of the treatment until disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: 1-2 years

07

Results

Posted Oct 14, 2026

Participant flow

Participant flow — Overall Study
MilestoneEndometrioid Histology CohortType 2 Histology Cohort
Started109
Completed89
Not completed20
Withdrew: Lack of efficacy20

Outcome measures

PrimaryProgression Free Survival (PFS) Rate at 12 Weeks

PFS will be calculated from the day of starting the treatment until 12 weeks. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) Rate at 12 Weeks
percentage of participantsEndometrioid Histology CohortType 2 Histology Cohort
Progression Free Survival (PFS) Rate at 12 Weeks12.511.1
PrimaryObjective Response Rate (ORR) as Determined by Response Criteria In Solid Tumors (RECIST) 1.1 Criteria

ORR will be calculated from the day of starting the treatment until disease progression. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
1-2 years
Reported as:
Number · percentage of participants with CR or PR
Objective Response Rate (ORR) as Determined by Response Criteria In Solid Tumors (RECIST) 1.1 Criteria
percentage of participants with CR or PREndometrioid Histology CohortType 2 Histology Cohort
Objective Response Rate (ORR) as Determined by Response Criteria In Solid Tumors (RECIST) 1.1 Criteria12.50
SecondaryDuration of Response

Duration of response will be determined from the time when a partial or complete response is seen until disease progression

Time frame:
1-2 years
Reported as:
Median · months
Duration of Response
monthsEndometrioid Histology CohortType 2 Histology Cohort
Duration of Response2.07 (NA to NA)—
SecondaryDuration of Stable Disease

Duration of stable disease will be calculated from the time of first treatment until disease progression

Time frame:
1-2 years
Reported as:
Median · months
Duration of Stable Disease
monthsEndometrioid Histology CohortType 2 Histology Cohort
Duration of Stable Disease9.66 (NA to NA)2.04 (1.38 to NA)
SecondaryMedian Progression Free Survival

Progression free survival will be calculated from the time of the start of the treatment until disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
1-2 years
Reported as:
Median · months
Median Progression Free Survival
monthsEndometrioid Histology CohortType 2 Histology Cohort
Median Progression Free Survival1.41 (1.38 to NA)1.38 (1.38 to NA)

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Endometrioid Histology Cohort2/10 (20%)2/10 (20%)8/10 (80%)
Type 2 Histology Cohort5/9 (55.6%)2/9 (22.2%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventEndometrioid Histology CohortType 2 Histology Cohort
Abdominal painGastrointestinal disorders0/102/9
DehydrationMetabolism and nutrition disorders1/101/9
Urinary obstructionRenal and urinary disorders1/100/9
AnemiaBlood and lymphatic system disorders1/100/9
Urostomy obstructionRenal and urinary disorders1/100/9
Acute kidney injuryRenal and urinary disorders1/100/9
HyponatremiaBlood and lymphatic system disorders1/100/9
SepsisGeneral disorders1/100/9
EncephalopathyNervous system disorders1/100/9
Most frequent other events
Showing 10 of 66
Most frequent other events
EventEndometrioid Histology CohortType 2 Histology Cohort
NauseaGastrointestinal disorders4/107/9
AnemiaBlood and lymphatic system disorders1/105/9
FatigueGeneral disorders4/105/9
AnorexiaMetabolism and nutrition disorders1/105/9
Peripheral Sensory NeuropathyNervous system disorders5/105/9
ConstipationGastrointestinal disorders4/104/9
VomitingGastrointestinal disorders2/104/9
Edema LimbsGeneral disorders1/104/9
DiarrheaGastrointestinal disorders3/103/9
HyperglycemiaMetabolism and nutrition disorders1/103/9

Baseline characteristics

Baseline analysis population includes patients evaluable for the study's primary endpoint

Age, Customized
Age, Customized(years)Endometrioid Histology CohortType 2 Histology CohortTotal
Mean age on study61.625 ± 9.18065.000 ± 10.05063.41 ± 9.51
Sex: Female, Male
Sex: Female, Male(Participants)Endometrioid Histology CohortType 2 Histology CohortTotal
Female8917
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Endometrioid Histology CohortType 2 Histology CohortTotal
Hispanic or Latino000
Not Hispanic or Latino8816
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Endometrioid Histology CohortType 2 Histology CohortTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White8715
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Endometrioid Histology CohortType 2 Histology CohortTotal
United States8917
08

Study locations

1 site
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Sep 2020, 39 months.

Results were first posted in Oct 2026, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2017
First posted
Apr 4, 2017
StartActual
Jun 8, 2017
Primary completionActual
Sep 9, 2020
CompletionActual
Sep 9, 2020
Results first posted
Oct 14, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 14, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedProgression free survivalFree Survival (PFS) rateRate at 12 weeksWeeksTime frame: 12 weeks
  • EditedObjective Response rateRate (ORR) as determinedDetermined by Response Criteria In Solid Tumors (RECIST) 1.1 criteriaCriteriaTime frame: 1-2 years
Oct 14, 2026
Documents
Secondary outcomes
3 edited, 1 removed
What changed in the outcomes
  • EditedDuration of responseResponseTime frame: 1-2 years
  • EditedDuration of stable diseaseStable DiseaseTime frame: 1-2 years
  • EditedMedian progression free survivalProgression Free SurvivalTime frame: 1-2 years
  • RemovedSafety profile of ONC201 will be determined by adverse events according to Common terminology criteria for Adverse Events (CTCAE) 4.03Time frame: 1-2 years
Oct 14, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 14, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedProgression free survivalFree Survival (PFS) rateRate at 12 weeksWeeksTime frame: 12 weeks
    • EditedObjective Response rateRate (ORR) as determinedDetermined by Response Criteria In Solid Tumors (RECIST) 1.1 criteriaCriteriaTime frame: 1-2 years
    Secondary outcomes 3 edited, 1 removed
    What changed in the outcomes
    • EditedDuration of responseResponseTime frame: 1-2 years
    • EditedDuration of stable diseaseStable DiseaseTime frame: 1-2 years
    • EditedMedian progression free survivalProgression Free SurvivalTime frame: 1-2 years
    • RemovedSafety profile of ONC201 will be determined by adverse events according to Common terminology criteria for Adverse Events (CTCAE) 4.03Time frame: 1-2 years
    + 5 other changes: verification date, oversight details, site details, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03099499
Collaborators
Oncoceutics, Inc.
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Jun 8, 2017
Primary completion
Sep 9, 2020
Completion
Sep 9, 2020
Results posted
Oct 14, 2026
Last update
Nov 3, 2026

Study contacts

Gina Mantia-Smaldone, MD
principal investigator · Fox Chase Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dordaviprone

Start the discussion